title: [Feeding regulatory peptides: hopes and limits for the treatment of obesities].
abstract: Excessive weight gain is directly related to a positive energy balance which is due to both a decreased physical activity and overeating. Obesity prevalence is increasing since thirty years and the treatment of obesities is particularly necessary to solve this public health and economical problem. The receptors of numerous hypothalamic neuropeptides are potential targets for such drug treatments. Hormones of the gastro-intestinal tract or produced by the adipose tissue directly interact with these central pathways to regulate feeding behavior. The use of leptin, an adipose tissue hormone that inhibits food intake, has not been conclusive because of the development of leptin resistance in obese subjects. Similar disappointing results have been obtained with antagonists of neuropeptide Y (NPY), one of the most potent orexigenic peptide. This was linked to the complexity and redundancy of the circuits involved in feeding regulation. Consequently, a multitherapy targeting several pathways simultaneously is probably the best option to cure obesity. Among these pathways, PYY 3-36 has been tested in man and some encouraging data have been obtained in animals with antagonists of some other orexigenic peptides such as orexins and melanin-concentrating hormone. A few gene therapy trials in the rat brain have restored interest for the leptin and NPY pathways. Their general use is however not planed in a next future. According to the type of obesity, these new treatments might be associated with either current (or almost current) drugs acting either on serotoninergic/catecholaminergic or cannabinoid pathways, or with surgery. Behavioral changes (food intake, exercise) and preventive actions during early life (in utero, young children) will remain for a while the best solutions to limit overweight development. The new treatments will help obese people to adhere to these behavioral changes by improving their efficiency to induce weight loss.
authors.affiliation: INSERM U724 et UHP/Neurocal, Faculté de Médecine, 9, avenue de la Forêt de Haye BP 184, 54505 Vandoeuvre-lès-Nancy, France. Bernard.Beck@nancy.inserm.fr
authors.forename: Bernard
authors.initials: B
authors.lastname: Beck
mesh_terms: D001067:Appetite Depressants / Q000627:therapeutic use; D005247:Feeding Behavior; D006801:Humans; D008954:Models, Biological; D009765:Obesity / Q000517:prevention & control*; D036361:Peptide Hormones / Q000502:physiology; D013312:Stress, Physiological / Q000503:physiopathology; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D001067:Appetite Depressants; D036361:Peptide Hormones